EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of NTQ5082 in Complement Inhibitor‐Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria

Li Zhang, Gaixiang Xu iD, Linghui Xia iD, Lin Liu, Yumeng Zhou, Rongfeng Zhou iD, Shujun Chen, Fengkui Zhang iD, Hongyan Tong

American Journal of Hematology · 30.10.2026

DOI: 10.1002/ajh.70512 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 30.10.2026. Verfasst von Li Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianj…. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Nanjing Chia-Tai Tianqing Pharmaceutical Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematologic disorder characterized by complement‐mediated intravascular hemolysis, pancytopenia, and thrombosis. NTQ5082 is a novel oral selective complement factor B (CFB) inhibitor that suppresses alternative pathway activity, thereby inhibiting intravascular hemolysis in PNH. We conducted a randomized, open‐label Phase 2 study to investigate NTQ5082 monotherapy in adults with PNH who had not previously received complement inhibitors. Twenty‐five patients were assigned to receive oral NTQ5082 once daily (QD) at 100 mg (group A) or 200 mg (group B) for 12 weeks. In both groups, lactate dehydrogenase (LDH) levels rapidly decreased, and hemoglobin (Hb) levels increased within 1 week after treatment initiation, with no further transfusions needed. At week 12, the mean LDH concentration was 239.4 ± 63.5 U/L in group A and 245.8 ± 72.6 U/L in group B. The Hb concentration increased to ≥ 20 g/L from baseline in 100% of patients, while 50% and 61.5% of patients in groups A and B, respectively, achieved Hb concentrations ≥ 120 g/L. The most frequently reported treatment‐related adverse events (TRAEs) were headache (12%), upper respiratory tract infection (8%), and decreased neutrophil count (8%); no grade ≥ 3 adverse events (AEs) were reported. Oral NTQ5082 administered at 100 or 200 mg QD effectively controlled hemolysis, significantly increased Hb levels, and improved quality of life, with a satisfactory safety profile, suggesting that NTQ5082 may represent a promising therapeutic option for complement inhibitor‐naïve patients with PNH.

Schlagwörter

Stichwörter der Autor:innen

NTQ5082hemoglobinlactate dehydrogenaseparoxysmal nocturnal hemoglobinuria

Autor:innen und Institutionen

  • National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
  • Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd., Nanjing, China.

ORCID-Profile: Gaixiang Xu, Linghui Xia, Rongfeng Zhou, Fengkui Zhang

Förderung

  • Nanjing Chia-Tai Tianqing Pharmaceutical Co. Ltd.

Zitieren

APA

Zhang, L., Xu, G., Xia, L., Liu, L., Zhou, Y., Zhou, R., Chen, S., Zhang, F., & Tong, H. (2026). Efficacy and Safety of NTQ5082 in Complement Inhibitor‐Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria. American Journal of Hematology. https://doi.org/10.1002/ajh.70512

Vancouver

Zhang L, Xu G, Xia L, Liu L, Zhou Y, Zhou R, et al. Efficacy and Safety of NTQ5082 in Complement Inhibitor‐Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria. American Journal of Hematology. 2026. doi:10.1002/ajh.70512

BibTeX
@article{Zhang2026,
  author = {Zhang, Li and Xu, Gaixiang and Xia, Linghui and Liu, Lin and Zhou, Yumeng and Zhou, Rongfeng and Chen, Shujun and Zhang, Fengkui and Tong, Hongyan},
  title = {Efficacy and Safety of NTQ5082 in Complement Inhibitor‐Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70512}
}
Kostenlos starten →